Merck has filed to expand Welireg’s label to include two combination regimens in kidney cancer pairing the HIF-2α inhibitor with Keytruda and with Lenvima, despite not yet having overall survival data. The company released preliminary results from combination readouts showing clinical activity that Merck says warrants regulatory discussion. Merck is pursuing accelerated access through demonstration of surrogate endpoints and tolerability in combo settings; regulators will scrutinize benefit-risk without mature survival outcomes. If approved, the label changes would broaden Welireg’s positioning in renal cell carcinoma and reshape competitive dynamics among adjuvant and advanced ccRCC regimens.